Recently, a Phase I clinical trial of a DLK inhibitor in ALS patients was halted after weeks of treatment due to observations of adverse effects including low platelet count, ocular toxicity, and altered touch sensation84. The gene discussed is MAP3K12; the disease is amyotrophic lateral sclerosis.